AU2827095A - Controlled release oral drug delivery system - Google Patents

Controlled release oral drug delivery system

Info

Publication number
AU2827095A
AU2827095A AU28270/95A AU2827095A AU2827095A AU 2827095 A AU2827095 A AU 2827095A AU 28270/95 A AU28270/95 A AU 28270/95A AU 2827095 A AU2827095 A AU 2827095A AU 2827095 A AU2827095 A AU 2827095A
Authority
AU
Australia
Prior art keywords
delivery system
drug delivery
controlled release
release oral
oral drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28270/95A
Inventor
Muhammad Baluom
Michael Friedman
Taher Nassar
Raphael Radai
Abraham Rubinstein
Boaz Tirosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2827095A publication Critical patent/AU2827095A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
AU28270/95A 1994-06-15 1995-06-13 Controlled release oral drug delivery system Abandoned AU2827095A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL110024 1994-06-15
IL110024A IL110024A (en) 1994-06-15 1994-06-15 Controlled release oral drug delivery system containing hydrogel- forming polymer
PCT/US1995/007519 WO1995034294A1 (en) 1994-06-15 1995-06-13 Controlled release oral drug delivery system

Publications (1)

Publication Number Publication Date
AU2827095A true AU2827095A (en) 1996-01-05

Family

ID=11066240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28270/95A Abandoned AU2827095A (en) 1994-06-15 1995-06-13 Controlled release oral drug delivery system

Country Status (3)

Country Link
AU (1) AU2827095A (en)
IL (1) IL110024A (en)
WO (1) WO1995034294A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086064A2 (en) * 1998-06-10 2001-03-28 Glycodesign Inc. Directed combinatorial compound library and high throughput assays for screening same
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
ES2385934T3 (en) 2004-08-20 2012-08-03 Mannkind Corporation CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA.
KR101644250B1 (en) 2004-08-23 2016-07-29 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
AU2007235251B2 (en) 2006-04-07 2013-02-07 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2009244799B2 (en) 2008-05-07 2014-11-20 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
ES2344673B1 (en) * 2008-08-07 2011-05-03 Italfarmaco, S.A. USE OF ESTRIOL IN THE PREPARATION OF A PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH RISK OF POTOLOGIATUMORAL.
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP5667095B2 (en) 2009-03-11 2015-02-12 マンカインド コーポレイション Apparatus, system and method for measuring inhaler resistance
CA2764505C (en) 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2579844B1 (en) 2010-06-10 2016-02-24 Midatech Ltd. Nanoparticle film delivery systems
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
ES2754388T3 (en) 2013-03-15 2020-04-17 Mannkind Corp Compositions and methods of microcrystalline dicetopiperazine
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD252539A1 (en) * 1986-09-17 1987-12-23 Berlin Chemie Veb METHOD FOR ORAL APPLICATION OF BIOLOGICALLY ACTIVE PEPTIDES WITH DELAYED EFFECT
JPH07138182A (en) * 1993-11-12 1995-05-30 Toyobo Co Ltd Sustained release type pharmaceutical preparation applicable to mucous membrane of oral cavity

Also Published As

Publication number Publication date
WO1995034294A1 (en) 1995-12-21
IL110024A0 (en) 1994-10-07
IL110024A (en) 1998-04-05

Similar Documents

Publication Publication Date Title
AU2827095A (en) Controlled release oral drug delivery system
AU3290397A (en) Gastric-retentive oral controlled drug delivery system with enhanced retention properties
AU8781798A (en) Sustained release drug delivery system suitable for oral administration
AU3204995A (en) Closed drug delivery system
AU5914999A (en) Controlled release drug delivery
AU664807B2 (en) Drug delivery system
AU6140598A (en) Multipathway electronically-controlled drug delivery system
AU4505496A (en) Sustained-release drug delivery system
AU4989993A (en) Drug delivery system
AU5676596A (en) Oral insulin delivery
AU1728797A (en) Comforter for delivering medicine
AU6558296A (en) Buccal delivery system for therapeutic agents
AU5945296A (en) Medicament for nasal administration
AU7493398A (en) Pulsatile drug delivery system
AU6876498A (en) Intravesical drug delivery system
AU6141199A (en) Multiplex drug delivery system suitable for oral administration
AU2999995A (en) Self-emulsifying drug delivery system
AU7711098A (en) Drug delivery system
AU7201998A (en) Drug delivery system
AU1709197A (en) Time release delivery system
AU7454698A (en) Improvement in medicament administration system
AU660290B2 (en) Multiple drug delivery system
AU7994694A (en) Controlled release oral delivery system containing oxybutynin
AU5401796A (en) Solid delivery form for oral use
AU3481497A (en) Chitosan drug delivery system